Dr Reddy's rolls out generic cancer drug
Dr Reddy's Laboratories has rolled out Gemcitabine for Injection (200 mg/vial and 1 g/vial) in the US market.
Dr Reddy's Gemcitabine for Injection is the generic version of a cancer medication, Gemzar.
Gemzar is indicated as a treatment for cancers of the pancreas, lung and breast as well as used in combination with carboplatin for the treatment of ovarian cancer.
The launching of the drug follows the US Food and Drug Administration approval for the abbreviated new drug application of Gemcitabine for injection.
Currently, Dr Reddy's Gemcitabine for Injection 200mg/vial and 1 g/vial strengths are available in single-use vials.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs